Company profile: Theravectys
1.1 - Company Overview
Company description
- Provider of a proprietary lentiviral vector platform for developing vaccines and immunotherapies to prevent and treat infectious diseases, cancers, and other conditions. Pipeline includes Lenti-HPV-07 (Phase 1) for HPV16/18-induced oropharyngeal and cervical cancers, Lenti-COVID intranasal vaccine for SARS-CoV-2 variants, and LV-DEN tetravalent T-cell dengue vaccine. Initial clinical focus includes HIV/AIDS.
Products and services
- Lenti-COVID: Engineers an intranasal, lentiviral vector-based vaccine candidate designed to induce mucosal immunity against SARS‑CoV‑2 and its variants
- Lenti-HPV-07: Produces a lentiviral vector-based vaccine candidate targeting oropharyngeal and cervical cancers induced by HPV16 or 18, currently advancing through Phase 1 clinical trials
- Lentiviral Vector Platform: Builds a proprietary platform optimized for safety and efficiency to develop vaccines and immunotherapies using lentiviral vectors across infectious diseases, cancers, and other conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theravectys
Palleon Pharmaceuticals
HQ: United States
Website
- Description: Provider of glycoimmune checkpoint inhibitors to treat cancer, including E-602, a bi-sialidase fusion protein in Phase 1/2 trials that degrades immunosuppressive sialoglycans to restore antitumor immunity; the EAGLE platform of engineered human sialidases to strip sialic acid from cancer and immune cells; HYDRA immunohistochemistry technology to quantify sialoglycan density; and autoimmune disease R&D programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palleon Pharmaceuticals company profile →
BlossomHill Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on oncology and autoimmune disorders, including FDA-approved repotrectinib (AUGTYRO) for ROS1+ NSCLC, crizotinib (XALKORI) and lorlatinib (LORBRENA), and pipeline candidates elzovantinib (TPX-0022) and TPX-0046, both in Phase 1 studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlossomHill Therapeutics company profile →
Eureka Therapeutics
HQ: United States
Website
- Description: Provider of T-cell therapies via the ARTEMIS Cell Receptor Platform to engineer T cells to target and destroy cancer cells; the E-ALPHA Phage Display Platform to generate specific antibodies against cancer targets, including TCR-mimic antibodies for solid tumors; and an Expanded Access Policy offering investigational cell therapy under certain conditions to patients with serious or life-threatening diseases who have no other treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eureka Therapeutics company profile →
Human Genome Sciences
HQ: United States
Website
- Description: Provider of global healthcare focused on helping people do more, feel better, and live longer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Human Genome Sciences company profile →
Valerion Therapeutics
HQ: United States
Website
- Description: Provider of therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valerion Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theravectys
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theravectys
2.2 - Growth funds investing in similar companies to Theravectys
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theravectys
4.2 - Public trading comparable groups for Theravectys
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →